Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
FDA: Replacement of extracellular fluid and electrolytes in patients with fluid and electrolyte deficits, maintenance of fluid and electrolyte balance during surgery or in postoperative patients.,Off-label: Treatment of metabolic acidosis, correction of electrolyte imbalances.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
The terminal elimination half-life for the individual electrolytes varies: Sodium has a half-life of approximately 2-4 hours depending on hydration and renal function; potassium has a half-life of 5-7 hours in normal renal function; magnesium has a half-life of 24-72 hours; calcium has a half-life of 3-6 hours. Clinically, the half-life is prolonged in renal impairment, necessitating dose adjustment.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Acetate and gluconate are metabolized via the tricarboxylic acid (TCA) cycle primarily in the liver, producing bicarbonate; acetate is also metabolized peripherally. Sodium, potassium, magnesium, and chloride are excreted renally with minimal hepatic metabolism.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
The electrolytes in ISOLYTE S are primarily excreted via renal elimination. Sodium and chloride are almost entirely excreted by the kidneys, with minimal biliary or fecal elimination (<2%). Potassium is predominantly excreted renally (90%), with approximately 10% eliminated via feces. Magnesium and calcium are mainly excreted in urine (70-80% for magnesium, 20-30% for calcium) with some biliary/fecal excretion. Acetate and gluconate are metabolized to bicarbonate and excreted renally.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Minimal protein binding for most electrolytes: sodium (<5%), potassium (<5%), chloride (<5%), and magnesium (20-30% to albumin). Calcium is 40-50% bound to albumin and other proteins. Acetate and gluconate are not protein bound.
Negligible for electrolytes and dextrose (<5%).
Sodium: Vd of 0.25-0.35 L/kg, reflecting distribution primarily in extracellular fluid. Potassium: Vd of 0.4-0.6 L/kg, distributed in both intracellular and extracellular fluid. Magnesium: Vd of 0.5-0.8 L/kg. Calcium: Vd of 0.2-0.3 L/kg. These values indicate that electrolytes distribute widely but predominantly in various body compartments.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Bioavailability is 100% for all components when administered intravenously. For oral administration (not applicable here), bioavailability would vary, but for IV formulation, complete bioavailability is assumed.
Intravenous: 100%.
For GFR <30 m L/min, use with caution and monitor electrolytes; dose reduction may be required based on serum potassium and other electrolytes.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalance.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Pediatric dosing is weight-based: 20-30 m L/kg as a single dose, then titrate based on clinical response and electrolyte levels.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Geriatric patients: use lower initial doses (e.g., 250-500 m L over 2-4 hours) and monitor for fluid overload and electrolyte disturbances due to decreased renal function.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of fluid overload and congestive heart failure in patients with renal impairment or cardiac disease.,Electrolyte disturbances: hypernatremia, hyperkalemia, hypermagnesemia, hyperchloremia, acidosis or alkalosis.,Use with caution in patients with severe renal impairment, liver disease, or conditions predisposing to electrolyte imbalances.,Avoid rapid infusion in patients with increased intracranial pressure.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hyperkalemia (elevated potassium levels).,Hypernatremia (elevated sodium levels).,Hypermagnesemia (elevated magnesium levels).,Acute renal failure with oliguria or anuria.,Hypersensitivity to any component.
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No specific food interactions. Monitor sodium and fluid intake in patients with hypertension, heart failure, or renal impairment.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Compatible with breastfeeding. ISOLYTE S is an electrolyte solution with no known excretion into breast milk; components are normal plasma constituents. M/P ratio not applicable.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No specific dose adjustments required during pregnancy. Dosing based on clinical assessment of fluid and electrolyte deficits; physiological changes in pregnancy may necessitate adjustments in infusion rate and volume.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ISOLYTE S is a balanced electrolyte solution for maintenance and replacement therapy. Contains acetate and gluconate as bicarbonate precursors; avoid in patients with severe metabolic alkalosis or hyperkalemia. Use with caution in renal impairment, heart failure, or edema. Monitor serum electrolytes, acid-base balance, and renal function. Do not administer simultaneously with blood products via same IV line due to risk of hemolysis.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution is used to replace fluids and electrolytes in your body.,Tell your doctor if you have kidney disease, heart failure, or fluid retention.,Report any swelling, shortness of breath, or irregular heartbeat.,Do not drink alcohol while receiving this treatment.,Follow any dietary restrictions as advised by your healthcare provider.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S is an electrolyte and fluid replenisher. It provides water and essential electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) to restore and maintain extracellular fluid volume and electrolyte balance. Acetate and gluconate are metabolized to bicarbonate, serving as bicarbonate precursors to help correct metabolic acidosis.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN PLASTIC CONTAINER is: Intravenous administration, typical adult dose is 500-1000 m L per hour, adjusted based on clinical status and electrolyte needs.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN PLASTIC CONTAINER is classified as Category C. FDA pregnancy category C. No well-controlled studies in pregnant women. Use only if clearly needed. No specific fetal risks known; risk-benefit assessment required.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.